ArticleOncology reports2020
lncRNA SNHG3 promotes breast cancer progression by acting as a miR‑326 sponge.
Article in Oncology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- Cancer-derived exosomal lncRNA SNHG3 promotes the metastasis of colorectal cancer through hnRNPC-mediating RNA stability of β-catenin.International journal of biological sciences · 2024Article
- Article
- Small nucleolar RNA host gene 3 functions as a novel biomarker in liver cancer and other tumour progression.World journal of gastroenterology · 2022Review
- SNHG3 could promote prostate cancer progression through reducing methionine dependence of PCa cells.Cellular & molecular biology letters · 2022Article
- Article
- LncRNA RP11-551L14.4 suppresses breast cancer development by inhibiting the expression of miR-4472.PeerJ · 2022Article
- Review
- Long noncoding RNA SNHG10 promotes colorectal cancer cells malignant progression by targeting miR-3690.Bioengineered · 2021Article
Corrections and comments
- Retraction · 2022-01-04Concerns/Issues about Data · Concerns/Issues about Image · Duplication of/in Image · Investigation by Third Party · Paper Mill · Results Not Reproducible · · see also: https://pubpeer.com/publications/BF66B97AADA7D42C25190977212658
- Retracted
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidence suggests that long noncoding RNA (lncRNA) small nucleolar RNA host gene 3 (SHNG3) plays crucial roles in the initiation and progression of various types of malignant cancers. Yet, the role played by SNHG3 in breast cancer as well as the associated mechanisms remain largely unclear. The expression of SNHG3 was detected in breast cancer tissues and cell lines by reverse‑transcription quantitative PCR (RT‑qPCR). Cell proliferation, colony formation, cell cycle distribution, migration and invasion abilities were detected by Cell Counting Kit‑8, colony formation assay, flow cytometry, wound‑healing and Matrigel invasion assays, respectively. The regulatory relationships between SNHG3 and miR‑326 were explored by luciferase reporter assay. A nude mouse model was established to investigate the effect of SNHG3 in vivo. The results showed an upregulation of SNHG3 in breast cancer tissues and cell lines. Loss‑of‑function assays revealed significant suppression of breast cancer behaviors such as: Abilities to proliferate, form colonies, migrate and invade in vitro coupled with a delayed growth of tumors in vivo when SNHG3 was knocked down. Mechanically, it was shown that SNHG3 served as a competing endogenous RNA (ceRNA) of miR‑326 that in turn is a tumor suppressor in this cancer. The correlation between the expression of SNHG3 and miR‑326 was found to be strongly negative in these samples. Additionally, we found that inhibition of SNHG3 caused a partially reversal in the inhibition exerted by miR‑326 on the ability of these cells to proliferate, form colonies, migrate and invade. Collectively, these findings suggest the functioning of SNHG3 as a ceRNA to enhance the ability of breast cancer cells to proliferate and metastasize to putatively serve as a new target to explore therapeutic intervention of this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.